Home
overview

SMi Group is proud to present its 2nd annual conference on Drug Discovery, taking place on 21st-22nd of March 2018 in Central London.
 

This conference will bring together key opinion leaders and senior industry experts to discuss the latest developments in drug discovery strategies. As the industry is experiencing radical changes in approaches to the discovery of new compounds, it is vital to look beyond to the next generation of enabling tools and technologies. This will assist rational, fast and successful drug discovery.


Drug Discovery 2018 provides an unprecedented opportunity to gain insight into the use of Artificial Intelligence in in silico drug discovery, as well as discussing 3D structure based-discovery, medicinal and discovery chemistry, translational medicine and the use of CRISPR cas-9 gene editing techniques and PROTAC's.
 

- Discover how leading pharmaceutical companies are incorporating Artificial Intelligence into their in silico drug discovery process!


- Gain insight into how CRISPR cas9 and PROTACs are being utilised to discover new drugs.


- Learn about the latest methods of predicting drug kinetics and toxicity early on in the pre-clinical process to speed up the drug discovery process and increase the potential success of newly discovered drugs.
 

AbbVie; AstraZeneca; Biogen; Bio-Mimetic Chromatography Consultancy; Cisbio Bioassays; Cresset Group; Eli Lilly & Co; Galapagos NV; GlaxoSmithKline; GSK; H. Lundbeck A/S; Heptares Therapeutics; Janssen Pharmaceutica NV; leadXpro AG; Merck KGaA; MRC Technology; National Institute Of Advanced Industrial Science And Technology; NovAliX; Novartis; Nycomed Pharma Private Ltd; OpenEye Scientific Software; Polyphor Ltd; Proximagen Ltd; Sanofi-Aventis; Schrodinger ; Takeda; The Cambridge Crystallographic Data Centre; The Drug Discovery Unit, University of Dundee; The University Of Newcastle; TissUse GmbH; UCB Pharma Limited; Univ of Dundee; University College London; University Of Leeds; Vernalis Research Ltd;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Darren Green

Darren Green, Director of Molecular Design, GSK
View Bio

9:10 KEYNOTE ADDRESS: Progress towards a contemporary medicinal chemistry technology toolkit

Stevan Djuric

Stevan Djuric, Vice President, Discovery Chemistry and Technology, AbbVie
View Bio

• Reducing cycle times and costs whilst improving the probability of technical success in the Drug Discovery process
• Advances in the development and introduction of several new enabling chemistry technologies, including flow photochemistry
• Integrating synthesis, purification and bioassay platforms
• Developing heterocycle synthesis by using a high temperature chemistry flow reactor

9:50 SMN2 splicing modifiers for the treatment of spinal muscular atrophy. A journey 'from bench to bed’

Hasane Ratni

Hasane Ratni, Expert Scientist, F. Hoffmann-La Roche Ltd.
View Bio

• Discovery of the first tool molecules
• Optimization of their profile, potency, safety and pharmacodynamics
• Discovery of the clinical candidate
• Discussion of the unique mode of action of a small molecule interaction with mRNA
• Presentation of some clinical data

10:30 Morning Coffee

11:00 Open access chemical probes

Susanne Muller-Knapp

Susanne Muller-Knapp, Senior Project Manager Chemical Probes, SGC Frankfurt, Goethe University Frankfurt
View Bio

• Chemical probes: essential tools in biology and target validation- the Epigenetic example
• Living a public-private partnership: the SGC tool box
• Boosting open access research: The Donated Chemical Probes program

11:40 High-quality chemical probes and drug discovery: a pharmaceutical industry perspective

Ursula Egner

Ursula Egner, Director, Head of Structural Biology, Bayer AG
View Bio

• The Bayer – SGC collaboration: Advancing drug discovery by open innovation
• Know your target: Chemical probes trigger a better preclinical understanding of target candidates
• The seeding effect of chemical probes: Discovery of new biology with Bayer’s SMYD2 probe BAY-598

12:20 Enabling Drug Discovery for Challenging Targets

Roderick  Hubbard

Roderick Hubbard, Professor & Senior Fellow, University of York & Vernalis Research
View Bio

• Establishing feasibility – solving problems in protein production and assays
• Generating structural insight when x-ray crystallography is tough
• Illustrated with recent work on Mcl-1 and Bcl-2 (both now in Phase I trials)

13:00 Networking Lunch

14:00 Artificially intelligent drug design

Gisbert  Schneider

Gisbert Schneider, Professor, Chair for Computer-Assisted Drug Design, ETH Zürich
View Bio

• De novo compound design in silico
• Target prediction and off-target profiling
• Automating drug discovery by machine learning

14:40 Transforming small molecule drug discovery using artificial intelligence

Andrew Hopkins

Andrew Hopkins, Professor & Chief Executive Officer, University of Dundee & Exscientia
View Bio

• Exscientia’s automated design process mimics human creativity by designing molecules which integrate the wealth of available data
• Discover how Exscientia’s AI is delivering pre-clinical candidates with exception productivity
• Learn how artificial intelligence and human expertise can be best combined to re-design the drug discovery process
• The potential of AI to increase the capital efficacy of R&D

15:20 Afternoon Tea

15:50 Disrupting drug discovery with AI

Mark Davies

Mark Davies, Vice President, Biomedical Informatics, BenevolentAI
View Bio

• Highlighting the data challenges faced by the Drug Discovery industry
• Describing how AI can offer solutions to these problems by augmenting the Drug Discovery process
• Providing an overview of the AI focused workflows and tools developed by BenevolentAI
• Demonstrating the success of BenevolentAI approaches with specific examples

16:30 Machine learning for smarter drug discovery

Claus Bendtsen

Claus Bendtsen, Executive Director & Head of Quantitative Biology, AstraZeneca
View Bio

• Advances in machine learning is now having a real impact on how drug discovery is done.
• Increase efficiency in early R&D through a deeper understanding of the quality of our predictions, together with the ability to integrate diverse sources of information to form accurate predictions.
• Learn how to make better decision on which experiments to perform
• Reduce costs by learning from our historical data
• Discover new biology through analytics

17:40 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Guido Hanauer

Guido Hanauer, Chief Executive Officer, GHPC GmbH

9:10 KEYNOTE ADDRESS: Drug discovery: transforming success through innovation and collaboration

Steve Rees

Steve Rees, Vice President Discovery Biology, Astra Zeneca
View Bio

• Application of the AstraZeneca 5R strategy for target selection
• Development of innovative capabilities for compound management and hit identification
• Transforming lead optimisation through the automation and miniaturisation of chemistry
• Developing a portfolio of diverse therapeutic modalities to enable any target to be prosecuted
• Innovative models of collaboration with pharma, vendor and academic partners

9:50 Validating and invalidating targets, is CRISPR enough?

William Janzen

William Janzen, Executive Director, Lead Discovery, Epizyme
View Bio

• The literature is full of misleading target validation references
• While a drug on the market is the ultimate validation of a target, there are biological and chemical steps along the way that lend credence to validation
• This talk will review and compare biological and chemical validation of targets

10:30 Morning Coffee

11:00 Applying multi-organ-on-a-chip technologies for predictive substance testing

Reyk Horland

Reyk Horland, Vice President, Business Development, TissUse GmbH
View Bio

• Overview of the organ-on-a-chip landscape
• Introduction to Multi-Organ-on-a-chip solutions
• Case studies of industrial adoption of (Multi)-Organ-on-a-chip models
• Roadmap towards regulatory validation

11:40 Drug Discovery in 3-Dimensions: A novel micro-scaffold-based approach for screening purposes – advantages and pitfalls

Gary Allenby

Gary Allenby, Business Development Director and Chief Scientific Officer, Aurelia Bioscience
View Bio

• We have developed a novel electrospun micro-scaffold based technology on to which we seed and grow recombinant cells, primary cell and differentiated stem cells
• These micro-scaffolds are magnetic, allowing each cell population to be manipulated in both culture tubes and assay plates. We have therefore use this approach to screen compounds in well plate based assays
• We will show data demonstrating the importance of 3-dimensional biology on micro-scaffolds used to generate a more physiological approach to testing compounds

12:20 Encoded library technologies in drug discovery

Christoph Dumelin

Christoph Dumelin, Laboratory Head, Novartis Institutes for BioMedical Research (NIBR), Novartis
View Bio

• Overview of small and mid-size encoded library platforms at Novartis
• Application of encoded library technologies to drug discovery projects
• Discussion of 1-2 case studies

13:00 Networking Lunch

14:00 Innovative modalities and business in the lead generation strategy

Patrick Jimonet

Patrick Jimonet, Director, External Innovation Drug Discovery, Sanofi
View Bio

• Limitation of current Hit finding strategies in a rapidly changing drug discovery environment
• Cyclic peptides, macrocycles: new modalities to drug challenging targets
• Examples of innovative business models, partnerships and crowdsourcing to enhance Lead Generation efficiency
 

14:40 Small-molecule induced protein degradation with PROTACs

John Harling

John Harling, Director of Chemistry for the Protein Degradation DPU, GSK

  • Small-molecule induced protein degradation represents an exciting new modality in drug discovery
  • This presentation will explain the basic science underlying this technology and how it offers unique opportunities for new medicines
  • Challenges in developing molecules with developable properties will be discussed
  • The scope of this technology will also be illustrated in terms of degradable targets and options for different E3 ligases
  • 15:20 Afternoon Tea

    15:50 Antibody-enabled small molecule drug discovery

    Alastair Lawson

    Alastair Lawson, Head of Structural Biology and Research Fellow, UCB
    View Bio

    • Antibodies have successfully addressed modulation of protein-protein interactions in the clinic, and can enable the discovery of small molecules, which modulate biology in similar ways.
    • Antibodies have already proved to be of significant value as chaperones in structural studies, and are being used to stabilise proteins in specific conformations, providing new and previously unexpected opportunities for intervention with small molecules.
    • Small molecule fragment screening against antibody-constrained targets offers the prospect of discovering new chemical entities, which would otherwise be unable to gain a foothold on proteins.  The approach is particularly well suited to the discovery of small molecules which modulate protein-protein interactions through binding at allosteric sites.
     

    16:30 Strategies to inhibit the intracellular target Ras with potent antibody mimetic proteins

    Ralph Minter

    Ralph Minter, Director, Fellow, Antibody Discovery and Protein Engineering, MedImmune
    View Bio

    • Ras mutations are strong oncogenic drivers of many cancers but the target Ras is still not addressed by current therapies
    • Using protein-based drugs to inhibit Ras is a novel approach
    • We describe antibody mimetic proteins which block Ras by locking it in an inactive conformation
    • These Ras inhibitory proteins enable us to explore the delivery of protein drugs into cells and study the biological implications of Ras inhibition

    17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Alastair Lawson

    Alastair Lawson

    Head of Structural Biology and Research Fellow, UCB
    Andrew Hopkins

    Andrew Hopkins

    Professor & Chief Executive Officer, University of Dundee & Exscientia
    Christoph Dumelin

    Christoph Dumelin

    Laboratory Head, Novartis Institutes for BioMedical Research (NIBR), Novartis
    Claus Bendtsen

    Claus Bendtsen

    Executive Director & Head of Quantitative Biology, AstraZeneca
    Darren Green

    Darren Green

    Director of Molecular Design, GSK
    Gary Allenby

    Gary Allenby

    Business Development Director and Chief Scientific Officer, Aurelia Bioscience
    Gisbert  Schneider

    Gisbert Schneider

    Professor, Chair for Computer-Assisted Drug Design, ETH Zürich
    Guido Hanauer

    Guido Hanauer

    Chief Executive Officer, GHPC GmbH
    Hasane Ratni

    Hasane Ratni

    Expert Scientist, F. Hoffmann-La Roche Ltd.
    John Harling

    John Harling

    Director of Chemistry for the Protein Degradation DPU, GSK
    Patrick Jimonet

    Patrick Jimonet

    Director, External Innovation Drug Discovery, Sanofi
    Ralph Minter

    Ralph Minter

    Director, Fellow, Antibody Discovery and Protein Engineering, MedImmune
    Reyk Horland

    Reyk Horland

    Vice President, Business Development, TissUse GmbH
    Roderick  Hubbard

    Roderick Hubbard

    Professor & Senior Fellow, University of York & Vernalis Research
    Stevan Djuric

    Stevan Djuric

    Vice President, Discovery Chemistry and Technology, AbbVie
    Steve Rees

    Steve Rees

    Vice President Discovery Biology, Astra Zeneca
    Susanne Muller-Knapp

    Susanne Muller-Knapp

    Senior Project Manager Chemical Probes, SGC Frankfurt, Goethe University Frankfurt
    Ursula Egner

    Ursula Egner

    Director, Head of Structural Biology, Bayer AG
    William Janzen

    William Janzen

    Executive Director, Lead Discovery, Epizyme

    Alastair Lawson

    Head of Structural Biology and Research Fellow, UCB
    Alastair Lawson

    Alastair is the Head of Structural Biology and a Research Fellow at UCB

    Alastair studied for his Ph.D. at the Tenovus Research Laboratory at Southampton General Hospital, where he worked with Professor George Stevenson on patient-specific, antibody-based therapy for leukemia. He joined Celltech as a research scientist in 1983, and has been closely involved with the discovery of therapeutic antibodies, including Cimzia®, Evenity®, olokizumab, dapirolizumab pegol and bimekizumab, together with antibody-drug conjugates, Mylotarg® and Besponsa®.

    Alastair led the development of UCB’s proprietary antibody discovery core platform, and currently heads UCB’s antibody-enabled small molecule drug discovery initiative, in which information from antibodies is applied to the discovery of new generations of small molecules addressing protein-protein interactions.
     

    Andrew Hopkins

    Professor & Chief Executive Officer, University of Dundee & Exscientia
    Andrew Hopkins

    Andrew Hopkins is the founder and CEO of Exscientia Ltd. Exscientia is the first company to automate drug design, using A.I., surpassing conventional human endeavors. Andrew is the author of some of the most highly cited papers in modern drug discovery. Prof Hopkins spent ten years at the Pfizer, following his DPhil at the University of Oxford. Subsequently, he was one of the youngest professors when he was appointed to a Chair at the University of Dundee. Prof Hopkins has raised around £50 million for commercial and academic research activities. He has won several awards for his work including the Royal Society of Chemistry’s Entrepreneur of the Year and the Capps Green Zomaya Medal, the BBSRC Commercial Innovator of the Year, Scottish Enterprise Life Science Entrepreneurial Leadership Award, and the Corwin Hansch Award. Andrew is a Fellow of the RSE, the RSC, the RSB and the LSW. Prof Hopkins lives in Oxford, UK.

    Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery.

    Christoph Dumelin

    Investigator III, Novartis Pharmaceuticals
    Christoph Dumelin

    Christoph Dumelin

    Laboratory Head, Novartis Institutes for BioMedical Research (NIBR), Novartis
    Christoph Dumelin

    Christoph E. Dumelin is a laboratory head at the Novartis Institutes of Biomedical Research in Basel, Switzerland, where he is applying different encoded library technologies to drug discovery projects. Before working at Novartis, he worked on DNA-encoded libraries at X-Chem Pharmaceuticals, Waltham, Massachusetts, USA, and on whole-blood pool contrast agents at Philochem, Zurich, Switzerland. He obtained his M.Sc. in biochemistry from the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, and his Ph.D. in pharmaceutical sciences at the ETH Zurich with Dario Neri. He completed his postdoctoral training in chemical biology with David Liu at Harvard University, Cambridge, USA.

    Claus Bendtsen

    Executive Director & Head of Quantitative Biology, AstraZeneca
    Claus Bendtsen

    Claus Bendtsen heads Quantitative Biology as part of Discovery Sciences within AstraZeneca. His department provides global support in areas of informatics, analytics, mathematical modeling, and non-clinical statistics. Prior to joining AstraZeneca he held positions at Novartis and Merck & Co. Earlier in his career he co-founded three start-ups and worked in academia. He holds a Ph.D. in applied mathematics and an MBA.

    Darren Green

    Director of Molecular Design, GSK
    Darren Green

    Darren Green is Director of Molecular Design, GlaxoSmithKline. Based at Stevenage, his group specialises in the application of molecular design, data analysis, predictive modelling and chemoinformatics methods to drug discovery. Darren also leads the Compound Collection Enhancement strategy for GSK.


    Darren has a PhD in Theoretical Chemistry from the University of Manchester and is a Fellow of the Royal Society of Chemistry.
     

    Gary Allenby

    Business Development Director and Chief Scientific Officer, Aurelia Bioscience
    Gary Allenby

    Gary Allenby, Aurelia Bioscience

    Biography:

    After completing a Ph.D. in reproductive toxicology I post-doc’ed at Hoffmann La Roche U.S.A, studying the pharmacology of retinoid biology. I returned to the U.K. into Lead Generation at Glaxo Wellcome, developing cell-based assays and working with vendors to validate new technologies for screening. In 2000 I joined Hit Identification at AstraZeneca, developing assays for respiratory and inflammatory disease and continuing to work with vendors.

    In 2011 I became a founding entrepreneur of Aurelia Bioscience, a pre-clinical contract research organisation specialising in the development of cell-based assays for compound and biologics screening. Our unique selling point is the development of more physiological phenotypic assays.
     

    Gisbert Schneider

    Professor, Chair for Computer-Assisted Drug Design, ETH Zürich
    Gisbert  Schneider

    Gisbert Schneider is a full professor at ETH Zurich, holding the Chair for Computer-Assisted Drug Design. He is recognized as being a pioneer in the integration of machine-learning methods into practical medicinal chemistry, and for his coining the phrases ‘scaffold-hopping’ and ‘frequent hitter’. His career has led him from the pharmaceuticals division at Roche to academia, initially to the Goethe-University in Frankfurt where he held the Beilstein Endowed Chair for Chem- and Bioinformatics, and then to his current position at ETH in Zurich. He is an elected Fellow of the University of Tokyo, and the recipient of the 2018 Herman Skolnik Award for his seminal contributions to de novo design of bioactive compounds. He has co-founded several start-up companies including inSili.com GmbH, AlloCyte Pharmaceuticals AG, and Endogena Therapeutics Inc.

    Guido Hanauer

    Chief Executive Officer, GHPC GmbH
    Guido Hanauer

    Hasane Ratni

    Expert Scientist, F. Hoffmann-La Roche Ltd.
    Hasane Ratni

    Dr H. Ratni is currently an Expert Scientist, Medicinal Chemistry, at F. Hoffmann-La Roche Ltd., pRED, Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland.
     

    He received his PhD at the University of Geneva and a post-doc at Tokyo before joining F. Hoffmann-La Roche Ltd in 2001. His research has mainly been devoted to the areas of neuroscience (for example neurokinin receptors, or V1a receptor antagonist now in human clinical trials, phase II, for autism). In 2005, he participated in a secondment within the Roche group at Chugai Pharmaceutical Co. Ltd, Gotemba Japan, in the field of renal disease. He was the chemistry discovery project leader of the SMN program aiming for a treatment for spinal muscular atrophy, now undergoing pivotal clinical trials in patients. His current focus is on gamma secretase modulator for Alzheimer disease.
     

    He is an author or co-author of more than 100 patents and publications. In 2014 he received the Roche Leo Sternbach Award for Innovation in Chemistry and in 2016 the Gold medal at the Roche Patent Inventor’s recognition event.
     

    John Harling

    Director of Chemistry for the Protein Degradation DPU, GSK
    John Harling

    Mark Davies

    Vice President, Biomedical Informatics, BenevolentAI
    Mark Davies

    Mark is the VP Biomedical Informatics at BenevolentAI. He has a background in molecular genetics, bioinformatics (BSc University of Sussex) and computer science (MSc Birkbeck College) and has over 15 years of experience working on biomedical data representation, data analysis and application development. In 2001, he joined the London based biotechnology company Inpharmatica, where he was initially working on mining the output of the Human Genome Project and eventually moved on to building chemogenomics and druggability assessment systems used by pharmaceutical companies, such as Bayer. Mark moved to the European Bioinformatics Institute (EMBL-EBI), as one of the founding members and technical lead for the ChEMBL database, the largest open-source Structure Activity Relationship (SAR) database. Mark was also responsible for the successful transition of the SureChEMBL chemical patent system from Digital Science to the EMBL-EBI.

    Patrick Jimonet

    Director, External Innovation Drug Discovery, Sanofi
    Patrick Jimonet

    Patrick Jimonet’s present role at Sanofi is to bring external innovation to the early portfolio and the Lead Generation process; his particular focus is on modalities, technologies and innovative biology through various and novel business models and partnerships.
    Previous assignments were the identification of key areas for improvement in early phases of discovery, leadership of a global interdisciplinary team responsible for the identification of novel GPCR targets and validated tool compounds to enter the portfolio of therapeutic units, manager of multi-cultural teams of Ph.Ds with project leadership positions, project leader of projects from hit finding to clinical candidate.
    All activities have been performed at Sanofi and predecessor companies in France and in the US. Patrick received his PhD in chemistry at the Institut de Chimie des Substances Naturelles of the CNRS in Gif-sur-Yvette, France.

    Ralph Minter

    Director, Fellow, Antibody Discovery and Protein Engineering, MedImmune
    Ralph Minter

    Following a PhD in Immunology from the University of Durham in 1999, Ralph has been working in Antibody Discovery and Protein Engineering (ADPE) at MedImmune, developing candidate therapies in the areas of oncology, autoimmune disease, asthma and infection. Several of these candidate drug molecules are now progressing through clinical trials (including the antibody Benlysta®, approved in 2011 for SLE). As Director, Fellow at MedImmune, Ralph actively pursues novel scientific and collaborative opportunities within the biologics field and has published 31 papers to date, covering diverse areas such as phenotypic drug discovery, antibody and protein engineering and novel target biology. His current focus is on the delivery of biological macromolecules into cells.

    Reyk Horland

    Vice President, Business Development, TissUse GmbH
    Reyk Horland

    Since 2010 Reyk is actively involved in the development of TissUse’s Multi-Organ-Chip platform for culture analysis of drug candidates, cosmetics, chemicals and consumer products. He currently holds the position of Head of Business Development at TissUse. Prior to TissUse Reyk studied Biotechnology at the Technische Universität Berlin and specialized in Medical Biotechnology. During his academic career, he was involved in various tissue-engineering programs, all with a focus on bringing the respective products to market.

    Roderick Hubbard

    Professor & Senior Fellow, University of York & Vernalis Research
    Roderick  Hubbard

    Professor Rod Hubbard has been an academic at York for over 35 years working with methods for analysis and exploitation of protein structure. He developed molecular graphics and modelling methods in the 1980s and helped build Structural Biology at York during the 1980s and 1990s. He worked on the structure of many proteins of therapeutic importance combined with studies of protein-ligand interactions and methods in structure-based design. In 1997, he was a founding SAB member of what became Vernalis. Since 2001 he has split his time between Vernalis (fragment and structure based drug discovery) and York (fragment methods for chemical biology and industrial biotechnology). In addition, he works with UK Research Councils and consults with pharmaceutical and technology companies around the world.

    Stevan Djuric

    Vice President, Discovery Chemistry and Technology, AbbVie
    Stevan Djuric

    Dr Stevan Djuric is head of the global AbbVie Medicinal Chemistry Leadership Team at Abbott and is also responsible for the Discovery Chemistry and Technology organization within their Discovery organization and chemistry outsourcing activities. The group’s current efforts are focused on new initiatives in the areas of high throughput synthesis and purification, hit to lead chemistry, chemical biology including target identification proteomics and new enabling technology identification and development.

    He was named an AbbVie Distinguished Research Fellow in 2015

    During his tenure at Abbott Laboratories, Dr Djuric has been a Project Leader for groups in the Immunoscience, Metabolic Disease, and Antiinfective areas. Several of these programs have advanced compounds into clinical development and to the market including Abbott’s proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe.

    Dr Djuric has over 180 scientific publications, presentations and patents/applications pending. He has also given over 30 invited lectures at universities and national meetings. He is a member of several Editorial Advisory Boards including the Journal of Medicinal Chemistry and ACS Medicinal Chemistry Letters and, in addition, holds an Adjunct Professorship in the Department of Medicinal Chemistry at the University of Kansas.
     

    Steve Rees

    Vice President Discovery Biology, Astra Zeneca
    Steve Rees

    Stephen Rees

    VP Discovery Biology, Discovery Sciences, AstraZeneca, Milton Science Park, Cambridge, UK

    In March 2017 Steve was appointed as Vice-President of the Discovery Biology department at AstraZeneca with global accountability for protein and cellular reagent generation and assay development, functional genomics and chemical biology. Prior to this Steve led the Screening Sciences and Sample Management department and successfully implemented strategies for hit identification, compound profiling, sample management and open innovation. Steve has led multiple international collaborations and has authored >60 scientific papers. Steve is currently Chair of the European Laboratory Research and Innovation group (ELRIG), has served as Chair of the SLAS Europe Council, is a member of the Scientific Advisory Board for Axol Biosciences, LifeArc and the Centre for Membrane Protein and Receptor research at the Universities of Nottingham and Birmingham.

    Susanne Muller-Knapp

    Senior Project Manager Chemical Probes, SGC Frankfurt, Goethe University Frankfurt
    Susanne Muller-Knapp

    Susanne Müller-Knapp studied Human Biology in Marburg Germany followed by a PhD in molecular biology at the Karolinska Institute in Stockholm, Sweden (1997). She then had more than 6 years of postdoctoral training in the area of inflammation and gene regulation at the Karolinska Institute and at the DIBIT San Raffaele Scientific Institute in Milan, Italy.
     

    In 2004 Susanne joined the Structural Genomics Consortium, SGC, in Oxford. The SGC is an international public private partnership that currently comprises 9 international pharmaceutical companies and a large network of academic and industrial collaborators. Susanne worked at the SGC first as External Research Manager and then Scientific Coordinator. She has been the Project Manager of the Epigenetic Probe Project, which generates tool compounds with defined specificity and selectivity for epigenetic targets and the cell based assay group at the SGC in Oxford testing the cellular activity of the in vitro characterised tool compounds. In her role as Senior project manager for chemical probes at the SGC Frankfurt Susanne is now coordinating several probe programs including the global SGC kinase chemical probe program and a program of probes donated by SGC partners.

    Ursula Egner

    Director, Head of Structural Biology, Bayer AG
    Ursula Egner

    Ursula Egner is the director of Structural Biology at Bayer AG, Berlin. She studied physics and obtained her PhD in protein crystallography at the University of Heidelberg and University of Freiburg. In a postdoctoral position in the protein crystallography group of Wolfram Saenger at the Free University of Berlin she expanded her knowledge of structural biology in modeling of protein-ligand complexes with a primary focus on herbicide binding proteins. In the early 1990s, she joined Schering AG, now Bayer AG, to build up a homology modeling platform for protein-ligand complexes and pursuing the establishment of a platform linking structural biology information to bioinformatics data. Since 2000, she is Director of Structural Biology. Ursula’s main research interest is to facilitate early small molecule drug discovery by druggability assessments of targets, X-ray crystallography and fragment screening for hit identification. Her group strongly contributes to lead generation and optimization in the therapeutic areas of oncology and cardiology.

    William Janzen

    Executive Director, Lead Discovery, Epizyme
    William Janzen

    William P. Janzen is the Executive Director of Lead Discovery at Epizyme, Inc. Mr. Janzen has over twenty five years of experience in innovative drug discovery and has been a leader in the field of lead generation in academia, start-up companies and large pharmaceutical ventures. He has held executive and operational positions including President and Chief Operating Officer of Amphora Discovery, Director of Lead Generation Technologies at Eli Lilly and Company and Director of Assay Development and Compound Profiling at the University of North Carolina. Mr. Janzen was a founder of the Society for Biomolecular Screening (SBS) and served as president from 1998 – 2000. He was also on the board of directors of the SBS and Society for Laboratory Automation and Screening. He assembled the definitive work on high throughput screening, High Throughput Screening Methods and Protocols and has subsequently edited second and third editions of the book. Mr. Janzen has worked on over 500 drug discover projects in his career including numerous projects that have entered clinical trials.

    Supporters

    Workshops

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Media Partners


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    SelectScience

    Supporters
    http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    RareBase

    Supporters
    http://www.rarebase.co.uk

    The RareBase Networking Portal links people and companies throughout the world with an interest in rare and paediatric diseases.


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Scidoc

    Supporters
    http://http://scidoc.org/index.php

    SciDoc is an Open Access publisher, aimed to facilitate the dissemination of research articles to the global community. SciDoc Publishers is established with a sole motive to disseminate knowledge among the scientific community. We as an Open Access publisher are on our way to be the world class leader in the provision of STM (Science, Technology and Medicine) Open Access content. This publishing model allows us to reach millions of readers and give them access to scientific publications- online, free of charge.


    evvnt Ltd

    Supporters
    http://www.evvnt.com

    evvnt enables people all over the world to fill their events utilising the most effective event listing sites on the web. Every minute, with little more than a click, more events and conferences appear in listings, in search engines and on mobile - discoverable by both category and location. With next to no effort customers of evvnt get better attendance, while consumers find events they previously had no idea existed. To date customers in 70 countries worldwide have submitted over 500,000 thousand event listings, created over 300,000 live links, and generated 1 million clicks to ticketing and registration pages. Learn more at www.evvnt.com


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Labiotech.eu

    Supporters
    http://labiotech.eu

    Labiotech.eu is the leading digital media covering the European Biotech industry. It is used by over 55000 people monthly to keep a watch on the business and innovations of biotechnologies.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.